Robert Hardi
George Washington University
11 Papers
25 Citations
Robert Hardi is an academic researcher from George Washington University. The author has contributed to research in topics: Placebo & Clinical endpoint. The author has an hindex of 6, co-authored 11 publications.
Chat about Author
Papers
A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease
William J. Sandborn,Subrata Ghosh,Julián Panés,Ivana Vranic,Wenjin Wang,Wojciech Niezychowski,Severine Vermeire,Olivier Dewit,Harald Peeters,Jiri Stehlik,Tomas Vanasek,David Laharie,Jean-Frederic Colombel,Marc-André Bigard,Marta Varga,Margit Zeher,Janos Novak,Béla Hunyady,Ágnes Salamon,István Rácz,Paolo Gionchetti,Anna Kohn,Cosimo Prantera,Pieter C. F. Stokkers,Maria Slomka,Leszek Paradowski,Tomasz Arlukowicz,Ladislav Kuzela,Boris Baricky,Tibor Hlavaty,Maria Isabel Vera,Jordi Guardiola,Chris Probert,Jonathan Shaffer,Mark R. Fleisher,Ronald E. Pruitt,John Sawyer Goff,John Weber,Raymond Lloyd Bell,Andrew Harrison Zwick,Alexandra Gutierrez,Robert H. Levine,Stephen Brett Hanauer,Lori Ann Lavelle,Ravindranath K. Kottoor,Gerald W. Dryden,Robert Hardi,David Vaughn Glorioso,Prabhakar Swaroop,Scott D. Lee,Teressa Joan Patrick,Sheldon Scheinert,Charles A. Sninsky,Seymour Katz,Mark D. Noar,Michael Marion Gaspari,Glenn L. Gordon,Thomas A. Dalton,Douglas Edward Homoky,William Ransom Kilgore,Joel A. Levien,Herbert R. Schneider,Suleman Abdul Moola,Frederik Cornelius Kruger,John P. Wright,Nazimuddin Aboo +65 more
TL;DR: There were no significant differences in the percentage of patients with moderate-to-severe active Crohn's disease who achieved clinical responses (Response-70) or clinical remission after 4 weeks' administration of tofacitinib or placebo twice daily.
287
Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study
Lloyd Mayer,William J. Sandborn,Yuriy Stepanov,Karel Geboes,Robert Hardi,Michael Yellin,Xiaolu Tao,Li-An Xu,Luisa Salter-Cid,Sheila Gujrathi,Richard Aranda,Allison Luo +11 more
TL;DR: Anti-IP-10 antibody, BMS-936557, is a potentially effective therapy for moderately-to-severely active UC and higher drug exposure correlated with increasing clinical response and histological improvement.
181
A Computer-Assisted Personalized Sedation System to Administer Propofol Versus Standard-of-Care Sedation for Colonoscopy and Esophagogastroduodenoscopy: A 1,000-Subject Randomized, Controlled, Multicenter, Pivotal Trial
Daniel J. Pambianco,Ronald E. Pruitt,Robert Hardi,Michael L. Weinstein,William C. Bray,Valli P. Kodali,John J. Vargo,Timothy T. Schubert +7 more
12